Alk­er­mes CEO Pops stays fo­cused on 5461 fil­ing plans; Shkre­li gets booed at Har­vard

• Alk­er­mes $ALKS is mov­ing ahead with plans to file a new de­pres­sion drug, ALKS-5461, lat­er in the year. “This is a fast-track des­ig­nat­ed med­i­cine,” CEO Richard Pops told an­a­lysts in Wednes­day’s quar­ter­ly call. “As we’ve done through­out the de­vel­op­ment process, ear­li­er this week we met with FDA for a Type C sci­en­tif­ic ex­change to share with them the da­ta from FOR­WARD-5. The meet­ing with FDA was pro­duc­tive, and we are on track with the plan sub­mis­sion of the NDA in the sec­ond half of the year.” And he is push­ing ahead with a care­ful eye on ALKS-3831, “which is com­ing in­to fo­cus as the piv­otal pro­gram ma­tures.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.